Laurence Berthier-Kraus
Oncology R&D Unit
Suresnes, France
Suresnes, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation.
Journal: Investigational new drugs
Published: March 14, 2020
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
Journal: Haematologica
Published: July 20, 2019
Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: November 27, 2018
Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice.
Journal: The Journal of pharmacology and experimental therapeutics
Published: June 30, 2018
Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma.
Journal: Gene
Published: November 23, 2015
Synthesis, antitumor activity, and mechanism of action of benzo[b]chromeno[6,5-g][1,8]naphthyridin-7-one analogs of acronycine.
Journal: Journal of medicinal chemistry
Published: November 01, 2014
Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: cooperative effects with cis-platin and radiotherapy on patient-derived xenografts.
Journal: PloS one
Published: November 08, 2013
The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 22, 2013
Last Updated: 09/26/2026